Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone604-629-9223
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25 million
Profitability
Miscellaneous
Employees8
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Neoleukin Therapeutics (NASDAQ:NLTX) Frequently Asked Questions
What is Neoleukin Therapeutics' stock symbol?
Neoleukin Therapeutics trades on the NASDAQ under the ticker symbol "NLTX."
When is Neoleukin Therapeutics' next earnings date?
Has Neoleukin Therapeutics been receiving favorable news coverage?
News articles about NLTX stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neoleukin Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Neoleukin Therapeutics.
Are investors shorting Neoleukin Therapeutics?
Neoleukin Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totalling 69,500 shares, an increase of 167.3% from the August 15th total of 26,000 shares. Based on an average trading volume of 156,900 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.3% of the shares of the stock are short sold. View Neoleukin Therapeutics' Current Options Chain.
Who are some of Neoleukin Therapeutics' key competitors?
Some companies that are related to Neoleukin Therapeutics include OvaScience (OVAS), OptiNose (OPTN), Atreca (BCEL), Avid Bioservices (CDMO), Syros Pharmaceuticals (SYRS), Theratechnologies (THERF), Kindred Biosciences (KIN), Ardelyx (ARDX), Kiniksa Pharmaceuticals (KNSA), Urovant Sciences (UROV), Cyclerion Therapeutics (CYCN), Geron (GERN), Dynavax Technologies (DVAX), Molecular Templates (MTEM) and Recro Pharma (REPH).
What other stocks do shareholders of Neoleukin Therapeutics own?
Who are Neoleukin Therapeutics' key executives?
Neoleukin Therapeutics' management team includes the folowing people:
- Mr. David J. Main, Co-Founder, Chairman & Pres (Age 54)
- Mr. Kamran Alam, CFO, VP of Fin. & Corp. Sec. (Age 45)
- Dr. Jonathan G. Drachman, Chief Exec. Officer (Age 57)
- Ms. Shelley McCloskey, VP of HR & Admin. (Age 59)
How do I buy shares of Neoleukin Therapeutics?
Shares of NLTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Neoleukin Therapeutics' stock price today?
One share of NLTX stock can currently be purchased for approximately $2.78.
How big of a company is Neoleukin Therapeutics?
What is Neoleukin Therapeutics' official website?
How can I contact Neoleukin Therapeutics?
Neoleukin Therapeutics' mailing address is 450-887 GREAT NORTHERN WAY, VANCOUVER A1, V5T 4T5. The company can be reached via phone at 604-629-9223 or via email at [email protected]
MarketBeat Community Rating for Neoleukin Therapeutics (NASDAQ NLTX)
MarketBeat's community ratings are surveys of what our community members think about Neoleukin Therapeutics and other stocks. Vote "Outperform" if you believe NLTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NLTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
